# Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

> **NCT02822495** · — · NO_LONGER_AVAILABLE · sponsor: **Atara Biotherapeutics**

## Conditions studied

- Epstein-Barr Virus (EBV) Infections
- Lymphoproliferative Disorders
- EBV+ Associated Lymphoma
- EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Epstein-Barr Viremia
- Lymphoma, AIDS-related
- Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID)
- Leiomyosarcoma (LMS)
- Nasopharyngeal Carcinoma (NPC)
- Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID)
- Solid Organ Transplant Complications
- Stem Cell Transplant Complications

## Interventions

- **BIOLOGICAL:** tabelecleucel

## Key facts

- **NCT ID:** NCT02822495
- **Lead sponsor:** Atara Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02822495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02822495, "Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02822495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*